The content on this site is intended for healthcare professionals only
Dr Benedikt Westphalen speaks to ecancer about the future of precision oncology.
There are several prerequisites to molecular profiling in cancer. This includes having access to quality-ensured testing, having the expertise to act on the results and gauging if the patients have access to the corresponding targeted treatment.
A few important questions need to be asked regarding the reasons behind testing and what will the outcome be.
Dr Westphalen further discusses clinical trials and how they can become the standard of care.
He concludes by talking about the potential of precision oncology and the direction it is headed.
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Durable responses in aRCC, how do we optimise treatment?
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
